Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 4;8(1):2.
doi: 10.1186/s40942-021-00343-3.

Future of anti-VEGF: biosimilars and biobetters

Monika Kapur  1 , Suvansh Nirula  2 , Mayuresh P Naik  3
Affiliations
Review

Future of anti-VEGF: biosimilars and biobetters

Monika Kapur et al. Int J Retina Vitreous. .

Abstract

The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). It is a matter of great concern that the US patents for Ranibizumab and Aflibercept expired in 2020 with European patents to expire in 2022 and 2025, respectively. With the expiry of these biologics, Biosimilars can prove to be saviours in the posterior segment pharmacotherapy owing to their cost effectiveness and availability of various options. Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and EMA soon. Biobetters are better than the original biologic in one or more parameters but require more research and development resources. With the emergence of better manufacturing and purification processes it is imperative that the biologics and biosimilars become better. The Ophthalmologists need to have in depth knowledge about these Biosimilars and Biobetters before these molecules take over the mainstream market.

Keywords: Anti-VEFG; Biobetters; Biosimilars.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Bevacizumab and Anti-VEGF Biosimilars for the treatment of neovascular age-related macular degeneration. https://www.ophthalmologymanagement.com/newsletters/amd-update/july-2020. Accessed Oct 2020.
    1. Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye. 2020;34:1008–1009. doi: 10.1038/s41433-019-0745-z. - DOI - PMC - PubMed
    1. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol. 2018;12:2137–2143. doi: 10.2147/OPTH.S180393. - DOI - PMC - PubMed
    1. Entine J. FDA balances costs, patient safety in the biologics, and personalized medicine revolution. Forbes. 2012. https://www.forbes.com/sites/jonentine/2012/07/23/fda-balances-costs-pat.... Accessed 23 Sept 2018
    1. Dimasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012. - DOI - PubMed